PD
The startup develops a low-cost liquid biopsy test for cancer detection and monitoring by utilizing real-time amino acid biomarkers through bioorthogonal chemistry. This assay quantifies healthy and disease states, providing patients with a scalable and affordable solution for cancer diagnostics.
Updated 18 months ago
Funding
$580K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NI
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a low-cost liquid biopsy test for cancer detection and monitoring by utilizing real-time amino acid biomarkers through bioorthogonal chemistry. This assay quantifies healthy and disease states, providing patients with a scalable and affordable solution for cancer diagnostics.